Navigation Links
Lilly Reports Third-Quarter 2011 Results
Date:10/20/2011

pment asset related to Amyvid.

The effective tax rate was 17.7 percent in the third quarter of 2011, compared with an effective tax rate of 22.0 percent in the third quarter of 2010. The largest driver of the decrease in the effective tax rate was the recognition of a $45.4 million discrete benefit primarily as a result of the resolution of the IRS audit of the company's 2007 federal income tax return. For the full year 2011, the company expects the effective tax rate to be approximately 19.5 percent.

Net income and earnings per share decreased to $1.236 billion and $1.11, respectively, compared with third-quarter 2010 net income of $1.303 billion and earnings per share of $1.18. The decreases in net income and earnings per share were primarily driven by lower operating income and higher other expense, partially offset by a lower effective tax rate.

Third-Quarter 2011 non-GAAP Results

Operating income decreased 8 percent to $1.611 billion, due to lower gross margin percent and increased marketing, selling and administrative expenses. Net income decreased 7 percent to $1.254 billion, while earnings per share decreased 7 percent to $1.13. These decreases were primarily driven by lower operating income and higher other expense, partially offset by a lower net effective tax rate. Excluding the impact of changes in foreign exchange rates, earnings per share would have decreased approximately 1 percent.

For purposes of non-GAAP reporting, items totaling $.02 and $.03 per share in the third quarters of 2011 and 2010, respectively, have been excluded. For further detail, see the reconciliation below as well as the footnotes to the non-GAAP income statement later in this press release.Third Quarter20112010

% GrowthEarnings per share (reported)$1.11$1.18(6)%Restructuring charges

.02.03Earnings per share (non-GAAP)  $1.13$1.21(7)%Year-to-Date Results

For the first nine months of 2011, worldwide total revenue was $18
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Lilly Declares Fourth-Quarter 2011 Dividend
2. Lilly Announces Changes in Senior Management
3. Lilly Confirms Date and Conference Call for Third-Quarter 2011 Financial Results Announcement
4. Lilly Improves Its Environmental Footprint in Business Operations and Helps Beautify Communities
5. Eli Lilly and Company Bringing Diabetes Education Program to the Annual Legislative Conference
6. Lilly Celebrates 17th Consecutive Year as One of Working Mother 100 Best Companies
7. Lilly Health Channel Debuts on YouTube
8. Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes
9. The American Diabetes Association and Eli Lilly and Company Encourage African Americans to Learn About Diabetes Through a Familiar Face
10. Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion
11. U.S. Court of Appeals Affirms Validity of Lillys Strattera Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... -- The management team at Columbia Laboratories, Inc. (Nasdaq: ... call on July 31, 2014, to discuss financial ... 2014.  The call details are as follows:Date: , ... numbers: , Toll free: (877) 870-4263 (U.S.), (855) ... , www.columbialabs.com , under ,Investor, or ...
(Date:7/23/2014)... SUNNYVALE, Calif. , July 23, 2014 /PRNewswire/ ... devices for the transcarotid treatment of intra- and ... Michael P. Wallace to the position ... Michael will lead the company,s Research and Development ... treatment devices. Prior to joining ...
(Date:7/23/2014)... July 23, 2014  Dompe, a leader in R&D for ... that rhNGF (Recombinant Human Nerve Growth Factor) has been designated ... Administration (FDA). The candidate drug, developed by ... drug for the treatment of neurotrophic keratitis, a degenerative corneal ... and is currently without a cure. This is the ...
Breaking Medicine Technology:Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 2Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 2Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 3Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 2Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 3Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 4
... DIEGO, April 20, 2012 /PRNewswire-iReach/ -- Nutrilys ... San Diego, has partnered with the Los Angeles Police ... armor. Nutrilys Del Mar founder, Thierry Lerond, journeyed to Los ... while helping them handpick the world,s best organic, ...
... 2012  Thoratec Corporation (NASDAQ: THOR ), a ... save, support and restore failing hearts, today announced that ... quarter of fiscal year 2012 on Tuesday, May 1. ... to discuss its financial results and operating activities, open ...
Cached Medicine Technology:Nutrilys Del Mar Joins Health Forces With LAPD Underwater Dive Unit 2Thoratec Schedules First Quarter Conference Call, Webcast 2
(Date:7/23/2014)... TX (PRWEB) July 23, 2014 Texas ... seven physical therapists from their Westlake, Westgate, Liberty Hill, ... earned the professional designation of Orthopaedic Certified Specialist ... this June. Adriana Juarez, PT, DPT, OCS, Tony Lauretta, ... Milligan, PT, DPT, OCS, Joseph Leech, PT, DPT, OCS, ...
(Date:7/23/2014)... July 23, 2014 CarePoint Health is ... hospital in New Jersey to receive the da Vinci® ... platform in the da Vinci series. This 4th generation ... step forward in innovation. The intuitive da Vinci Xi ... wide spectrum of minimally invasive and complex surgical procedures. ...
(Date:7/23/2014)... July 23, 2014 Recently, Agebc.com has ... Now, the company is announcing a promotion of wedding ... promotion will end at the end of this month. ... many popular styles, like A-line, mermaid, ball-gown, empire, and ... dresses and other special-occasion dresses for women, and the ...
(Date:7/23/2014)... In its latest blog post, Best ... having family close by during a stay in rehab can ... is successful, is focusing on a topic that is quickly ... dialogues: opiate abuse facts. , The Best Drug Rehabilitation blog ... An overview of opiates, and why they’re considered “the mother ...
(Date:7/23/2014)... Europe Drilling fluid and Completion fluid Market Report defines and ... with analysis and forecast of revenue. The drilling fluid and ... around $1.3 billion in 2013 to $1.7 billion by 2018, ... Browse through the TOC of the Europe drilling fluid and ... in-depth analysis provided. This also provides a glimpse of the ...
Breaking Medicine News(10 mins):Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 2Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 3Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 2Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 3Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 4Health News:Agebc.com Launched Its New Collection of Wedding Dresses 2Health News:Latest Best Drug Rehabilitation Blog Post Focuses on Opiate Abuse Facts 2Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 5Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 6
... is widely accepted that urgent endoscopy for UGIB should be performed ... time, it is still unclear whether it should be performed either ... more delayed interval, such as after 6, 12 or 24 hour. ... been yet established. , A research article to be published on ...
... Brazos Valley residents,neuroscience researchers, and interested clinicians will ... on the,topic of stroke during the Texas Brain ... 19. This year,s symposium will consist of a,morning ... for clinicians,and researchers. The speakers are both neuroscience ...
... Dialysis Providers, Patient Advocates Work with Local Kidney,Community ... Texas, Sept. 9 With the,highest per capita ... the,Gulf Coast region is bracing to avoid a ... disrupt the administration of,life-saving dialysis treatments to area ...
... 9 Encorium Group, Inc.,(Nasdaq: ENCO ), ... studies in over 30 countries for many of ... that it,has entered into an amendment (the "Amendment") ... Inc. ("Prologue"). Pursuant to the,Amendment, the Company will ...
... Correction of Familial Risk Estimates Increases Estimated Melanoma Risk ... The relative risk of familial melanoma increases substantially when ... large cohort study. The relative risk of familial lung, ... with the correction. , Researchers have used the Swedish ...
... in the United States undergo lung surgery each year, ... their care. In the current issue of The ... proposed a system of lung surgery quality indicators for ... best practices for obtaining positive patient outcomes. , Death ...
Cached Medicine News:Health News:Texas Brain and Spine Institute to Hold Second Annual Neuroscience Symposium 2Health News:Gulf Coast Dialysis Caregivers, Volunteers Brace for Hurricane Ike; Prepare to Maintain Power, Continued Access for Patients to Life-Saving Treatment 2Health News:Prologue Acquisition Update and Termination of Linkcon Business Combination 2Health News:Prologue Acquisition Update and Termination of Linkcon Business Combination 3Health News:Prologue Acquisition Update and Termination of Linkcon Business Combination 4Health News:Prologue Acquisition Update and Termination of Linkcon Business Combination 5Health News:Also in the Sept. 9 JNCI 2Health News:Also in the Sept. 9 JNCI 3Health News:Mayo Clinic chest surgeons propose measures for indicating quality of lung surgery 2Health News:Mayo Clinic chest surgeons propose measures for indicating quality of lung surgery 3
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... Precision Hand Instruments were developed in surgeon's ... while still having an instrument with the ... the fear of the bending or breaking. ... manufactured to conform to the surgeon's hand. ...
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
Medicine Products: